410 results on '"Roffler, Steve R."'
Search Results
2. Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)
3. Interactions between nanoparticle corona proteins and the immune system
4. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture
5. Glucuronides: From biological waste to bio-nanomedical applications
6. Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group
7. The interplay between membrane topology and mechanical forces in regulating T cell receptor activity
8. Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy
9. Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis
10. Liposomes with Low Levels of Grafted Poly(ethylene glycol) Remain Susceptible to Destabilization by Anti-Poly(ethylene glycol) Antibodies.
11. Replacement of L-amino acid peptides with D-amino acid peptides mitigates anti-PEG antibody generation against polymer-peptide conjugates in mice
12. Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma
13. Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicity
14. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity
15. Structural basis of polyethylene glycol recognition by antibody
16. Data from PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy
17. Data from Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies
18. Supplementary information from Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies
19. Supplementary Figure S1 from Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies
20. Supplementary Figure S1 from PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy
21. Supplementary methods from PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy
22. Supplementary Data from Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy
23. Supplementary Video 1 from Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy
24. Supplementary Data from Tumor-Localized Ligation of CD3 and CD28 with Systemic Regulatory T-Cell Depletion Induces Potent Innate and Adaptive Antitumor Responses
25. Supplementary Figure 2 from In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate
26. Supplementary Figure 3 from In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate
27. Supplementary Methods, Figure Legends 1-3 from In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate
28. Supplementary Video 2 from Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy
29. Supplementary Figure 1 from In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate
30. Supplementary Table 1 from Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
31. Supplementary Table 2 from Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
32. Supplementary Figure 3 from Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
33. Supplementary Figure 1 from Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
34. Supplementary Methods and Materials from Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
35. Supplementary Figure 2 from Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
36. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines
37. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus
38. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles
39. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
40. Transient AID expression for in situ mutagenesis with improved cellular fitness
41. Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment
42. Endothelial SCUBE2 Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis
43. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy
44. A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor
45. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies
46. Measurement of Poly(ethylene glycol) by cell-based anti-poly(ethylene glycol) ELISA
47. Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies
48. Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin
49. Hapten-directed targeting to single-chain antibody receptors
50. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.